Royalty Pharma plc

The conference will begin shortly. To raise your hand during Q&A, you can dial star 1 1. The conference will begin shortly. To raise your hand during Q&A, you can dial star 1-1.

Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Farmer Third Quarter Earnings Conference Call. I would now like to turn the call over to George Grafik, SVP, Head of Investor Relations and Communications. Please go ahead, sir.

Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's third quarter 2022 results. You can find the press release with our earnings results and slides to the call on the investors' page of our website at royaltypharma.com. Moving to slide three, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from these statements. I refer you to our 10-K on file with the SEC for description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP financial measures will be used to help you understand our financial performance The GAAP and non-GAAP reconciliations are provided in the earnings press release available on our website. And with that, please advance to slide four. Our speakers on the call today are Pablo Legareta, Founder and Chief Executive Officer, Marshall Uris, EVP, Head of Research and Investment, and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Marshall will provide a portfolio update, and Terry will review the financials. Following concluding remarks from Pablo, we will hold the Q&A session. Chris Tite, our Vice Chairman, will also join the Q&A session. And with that, I'd like to turn the call over to Pablo.